can result in functional limitations because of progressive joint damage and increased cardiovascular morbidity because of long-term systemic inflammation (1) (2) (3) . Major advances in management have occurred during the last 10-15 years, with quicker diagnosis, more rapidly acting disease-modifying antirheumatic drugs (DMARDs), more numerous therapeutic options, and implementation of dynamic disease activity2based strategies targeted at achieving low disease activity or remission (1, 4) . This ambitious therapeutic objective is reached in up to 50% of patients depending on the tool or criteria used to define low disease activity or remission (5) .
Nevertheless, RA flares may occur, because disease flares are one of the constitutive features of RA (6) (7) (8) (9) (10) (11) . In addition, disease activity may fluctuate on a daily basis between physician visits (12) , even in patients with low disease activity or disease in remission, with a frequency of approximately 50% in the maintenance arm of the PRESERVE trial (13) . This situation is of high importance, because such disease activity fluctuations have been associated with worse structural outcome. A previous study by Welsing et al demonstrated that both a higher mean Disease Activity Score in 28 joints (DAS28) (14) and larger DAS28 variability over time are associated with increased progression of structural damage in RA patients followed up over a 3-year period (15) . In that study, a patient with a low mean DAS28 and high DAS28 variance had a risk of progression similar to that of a patient with a high mean DAS28 and low DAS28 variance. The concept of disease flare may vary between health professionals and patients and among patients themselves, because of cultural background or different perceptions of the disease (7) (8) (9) .
Recently, our group developed a self-administered questionnaire, the FLARE-RA, to capture current or recent (i.e., in the previous 3 months or between 2 visits to the rheumatologist) RA flare, either transient during a few days or more prolonged (10) . The aim of the FLARE-RA is to identify patients with fluctuating disease activity and suboptimal control of their disease; thus, the FLARE-RA differs from currently available disease activity selfassessment instruments (16) (17) (18) . The FLARE-RA questionnaire is available in several languages after crosscultural adaptation conducted according to international guidelines (10, 19) . The objective of the present study was to validate the metrologic properties of the FLARE-RA questionnaire in a 3-month prospective observational study.
PATIENTS AND METHODS
Study design. The study was designed to validate the FLARE-RA self-administered questionnaire (10) according to the Outcome Measures in Rheumatology (OMERACT) 1.0 filter and the COSMIN (Consensus-based Standards for the Selection of Health Status Measurement Instruments) methodologic standards (i.e., content validity, reliability, construct validity, and feasibility) (20) (21) (22) (23) . For this purpose, a prospective longitudinal 3-month study was started in 13 rheumatology centers in France.
Patients. The inclusion criteria were age $18 years, RA diagnosis according to the 1987 American College of Rheumatology (ACR) (24) and/or 2010 ACR/European League Against Rheumatism (4) classification criteria, disease evolving for $6 months, treatment with synthetic or biologic DMARDs for $2 months, and stable symptomatic treatment (including steroids, if prescribed) for $2 months. We excluded patients with a planned surgical procedure, those who were under guardianship or were unable to comply with protocol recommendations including language issues, and those lacking insurance coverage. During follow-up of this observational study, no specific instruction was given regarding what must be considered as being an RA flare and how it could be selfmanaged.
Collected data. The following information was collected at baseline: age, sex, body mass index, major comorbidities, and occupation (in 7 categories; National Statistics Institute). The following main disease characteristics were recorded: RA duration, status according to serum rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA), presence of structural damage on radiographs, and previous DMARDs received.
At baseline and at the 3-month visit, the following information was collected: ongoing RA treatments, morning stiffness as well as night awakening due to joint pain, number of tender and/or swollen joints (44 assessed), patient's and physician's global assessments, erythrocyte sedimentation rate (ESR) and C-reactive protein level, DAS28, as well as treatment decision at the end of the visit (classified as unchanged, DMARD dose increase, switch to another DMARD because of loss of efficacy, switch to another DMARD because of a safety issue, or DMARD de-escalation). In addition, Routine Assessment of Patient Index Data 3 (RAPID-3) questionnaires were completed at baseline and 3 months, as well as every week in between, for a continuous measurement of disease activity (25) . Functional limitation and disease impact were assessed by the Health Assessment Questionnaire (HAQ) (26) and the Rheumatoid Arthritis Impact of Disease (RAID) scale (27) at baseline and 3 months. Finally, patients were asked the following question regarding flare occurrence: "Over the past 3 months (or since the last consultation), do you think you have experienced a flare of your rheumatoid arthritis? No, Yes once or Yes several times."
RA flare. The assessment of disease activity exacerbation in the 3 months between the 2 study visits was based on the FLARE-RA questionnaire, which has been described elsewhere (10) . Briefly, the questionnaire includes 13 questions examining 13 domains identified as being associated with RA flare by both patients and physicians (joint swelling, joint pain, night awakening, pain killer intake), only patients (fatigue, impossibility to do a thing, need for help, withdrawal from social activities, bad mood, and irritability), or only physicians (morning stiffness, daily dose of steroids, patient's global assessment). Every domain was formulated as follows: "In the last 3 months, or at some time since the last medical 310 FAUTREL ET AL consultation, please indicate how true the statement fits for you." For each statement, the respondent had to indicate agreement, using a numerical rating scale from 0 (completely untrue) to 10 (absolutely true). The total FLARE-RA score was the mean of the scores for the 13 items. Statistical analysis. The FLARE-RA questionnaire was assessed by descriptive statistics exploring the shape of the distribution of answers to each of the 13 items, the presence of a floor or ceiling effect, and calculating the score as the mean of item scores, only if ,50% of items had a missing answer. Factor analysis was performed to assess the construct validity and the dimensionality of the questionnaire according to 3 criteria: the Cattel scree test, Kaiser criterion (eigenvalue .1), and Horn's parallel analysis rule (28) , an estimation based on .1 criterion as recommended (29) to avoid overestimating the number of dimensions.
Calibration of the FLARE-RA questionnaire was investigated based on the item response theory, which describes the level of a subject's characteristics on the measured outcome (or "underlying trait") as a function of responses to the items as well as item properties. Analyses were conducted using the Rasch measurement method, globally and separately for each subdomain identified on factor analysis. We used partial credit models (30) with distance between response categories constrained to be equal within each item. Fit of the data to the Rasch model was assessed with standardized residuals and examination of the item characteristic curves. Unidimensionality of the global domain and each subdomain was verified by chi-square test and principal components analysis of the residuals. The internal consistency of the global domain and subdomains was examined with a person separation index (PSI) (31) . A PSI of .0.85 requires scores at the individual level.
The invariance of the scales was measured by assessing differential item functioning (32) across several factors: age, sex, and flare occurrence. Residual correlation matrices were examined to determine local independence of the scales. Local dependence of 2 items is detected when the correlation of their residuals is greater than that of the residuals between most pairs of items.
Reproducibility was explored by a test-retest experiment 2 days before and on the day of the 3-month visit. The concordance in the 2 successive measures for total score and 2 subscores was studied by the intraclass correlation coefficient (ICC) and Bland-Altman graphics. The smallest detectable difference (1.96 SD of the mean) was assessed.
Convergent validity was first investigated by correlation analysis of the FLARE-RA total and subdomain scores at baseline and month 3 with the DAS28, RAPID-3, RAID, and HAQ at the same visits as well as the area under the receiver operating characteristic curve (AUC) for weekly RAPID-3 measures, maximum RAPID-3 value, and maximum change in the RAPID-3 measures between month 0 and month 3 in the whole sample and in patients with low disease activity or disease in remission at month 3. In addition, the FLARE-RA scores at month 3 and changes in FLARE-RA scores between month 0 and month 3 were compared between different groups of patients with available data at month 3, according to 2 methods: 1) identification of 1 or several RA flares between month 0 and month 3 according to an anchor question ("In the last 3 months, do you think your RA has a flare? No/Yes once/Yes several times"), and 2) change in DAS28 between month 0 and month 3, i.e., DDAS28 #1.2 (improvement), 21.2 , DDAS28 , 1.2 (no significant change), or DDAS28 .1.2 (deterioration). Finally, discrimination was assessed by comparing the mean FLARE-RA and subdomain scores depending on the physician's treatment decision at the end of the month 3 visit. All analyses were performed using SAS version 9.3.
Ethics approval. The study was approved by the ethics committee of Nancy University Hospital. All patients underwent clinical examination and gave their written consent to participate in the study. 
RESULTS
The characteristics of the 138 patients included in the study are shown in Table 1 . Briefly, the characteristics of the study population corresponded to those of an established RA population, with ;80% of the participants having serum autoantibody positivity (RF or ACPA) or erosive disease. At baseline, mean 6 SD disease activity was low (DAS28 2.9 6 1.2, swollen joint count 1.9 6 2.9, tender joint count 3.0 6 4.7, and ESR 17 6 13.3 mm/hour). Overall, 63 patients (45.7%) reported a disease flare during the 3 months before inclusion in the study.
FLARE-RA item distribution and statistics. As shown in Table 2 , very few data were missing: 94% and 97% of the questionnaires had no missing items at month 0 and month 3, respectively (99% and 99%, respectively, for the FLARE-RA arthritis subscale, and 96% and 98%, respectively, for the FLARE-RA general symptoms subscale). The mean value for the 13 items ranged from 0.8 at baseline to 3.4 at 3 months ( Table 2) . The highest values were for the item on fatigue, which was also the item with the lowest floor effect (26.3% at baseline and 23.7% at 3 months). In contrast, lower values were expressed for the item on steroid intake increase because many patients chose 0, with lack of steroid use. Therefore, the floor effect was maximal for this item, reaching 77.4% at baseline and 82.5% at 3 months. Fourteen and 20 patients had a FLARE-RA score of 0 at month 0 and month 3, respectively. Their mean 6 SD DAS28 was 1.64 6 0.9 and 1.91 6 0.9, respectively. In addition, no substantial ceiling effect was observed for any item.
Dimensionality. Factor analysis for 125 patients with complete data identified 3 principal factors according to the Kaiser criterion, with the first 1 explaining 65.6% of the variance and the other 2 explaining 9.8% and 6.9%. According to Horn's parallel analysis rule and the Cattel scree test, only 1 factor was identified. The distribution of the 13 items among the 3 main factors is shown in Figure 1 . The first factor represented unidimensionality of flare (all items were on the same side). The second factor contrasted general or emotional symptoms (i.e., fatigue, limitations, irritability, mood, withdrawal, and need for help) to items directly related to arthritis (i.e., morning stiffness, night pain, swollen or tender joints, overall arthritis assessment, and increased intake of analgesics). Finally, a third factor was suggested with 1 item: increase in steroid intake. The steroid item appeared substantially apart from the other items and, combined with the substantial floor effect, was considered difficult to integrate into the global scale. This item concerned only 20% of the population who were treated with steroids at the time of the study, and was correlated with none of the other items except the item exploring daily analgesic intake (r 5 0.52). For all of these reasons, it was considered not as a genuine RA flare feature but as a behavioral feature in reaction to it and was eliminated from subsequent analyses. Figure 1 shows item loadings after varimax rotation on 2 independent factors: general/emotional and arthritis-related.
Questionnaire calibration. First, the item-fit analysis in the partial credit model indicated that the following 3 items did not satisfy the independence criteria: overall worsening of arthritis, increased daily dose of analgesics, and fatigue (particularly tired for several consecutive days). After discussion, the item on overall worsening of arthritis was eliminated, because it was considered redundant with the other arthritis-related items. The other items were retained in the questionnaire for reasons of content validity: they were considered highly important among physicians (daily analgesic intake) and patients (fatigue) (10). 
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The final model based on 11 items had a PSI of 0.93, which corresponds to excellent internal consistency. The partial credit model confirmed the ordering of response categories for each item (Figure 2A) . The person-item threshold distribution showed adequate distribution except for patients at the extreme left of the continuum, which is explained by half of the sample not reporting any flare ( Figure 2B ). Finally, we observed no differential item functioning according to age, sex, or flare in the previous 3 months or since the last visit.
FLARE-RA scores, internal consistency, and reproducibility. The FLARE-RA scores for the 11 items were 2.3 6 2.3 (total), 2.3 6 2.4 (arthritis-related subscale), and 2.4 6 2.4 (general subscale) at baseline ( Table 2 Figure B) showed ,5% of points (4.6%) outside the confidence interval; the mean 6 SD difference between the 2 measures was 20.24 6 0.82, for a smallest detectable difference of 1.61.
Convergent validity. The convergent validity was assessed in 3 ways. First, the FLARE-RA total score and the 2 subdomain scores showed high correlation with data for 4 outcome measures collected at the same time as the FLARE-RA questionnaire (Table 3) . 
FLARE-RA QUESTIONNAIRE TO DETECT RA FLARE
The strength of correlation between FLARE-RA scores and the DAS28 was fair (r 5 0.59-0.63, P , 0.001).
There were some fluctuations depending on the DAS28 level, with correlation coefficients of 0.31, 0.66, and 0.44 between the total score and the DAS28 for patients with disease in remission, low disease activity, or moderate-to-high disease activity, respectively. The correlation was greater using RAPID-3 (r 5 0.72-0.77, P , 0.001). The correlation was also substantial using the RAID index, which was used to explore disease impact (r 5 0.72-0.80, P , 0.001), but not with the HAQ, which was used to investigate functional limitations (i.e., disease activity and disease-related irreversible damage). Second, the capacity of the FLARE-RA questionnaire to identify disease activity exacerbation that occurred before the visit to the rheumatologist was assessed by the correlation between FLARE-RA scales and the integrated disease activity in the 3 months preceding the visit, as assessed by the weekly RAPID-3 (Table  3) . For the population with no missing data for the RAPID-3 assessment (n 5 96), we observed a significant correlation between the FLARE-RA at month 3 and RAPID-32based disease activity, as expressed by the RAPID-3 AUC (r 5 0.68), the maximum RAPID-3 value (r 5 0.75), or change over the 3-month period (r 5 0.48). The same findings were observed for patients with low disease activity or disease remission at the month 3 visit (n 5 54). However, the strength of the correlations was weaker (and sometimes not statistically significant) in the population with moderate-to-high disease activity.
Third, regardless of the anchor, FLARE-RA scores were significantly different between the groups, with the highest scores observed in patients with several self-reported RA flares (Table 4) or those with an increase in the DAS28 (Table 4) . The correlation between change in the DAS28 and change in the FLARE-RA arthritis subscore between month 0 and month 3 was statistically significant, with an ICC of 0.22 (95% CI 0.04-0.38).
Construct validity. At the month 3 visit, 117 patients were considered stable and continued to receive the same DMARD; the mean FLARE-RA score in this group was 2.2. Five patients discontinued their ongoing DMARD due to loss of efficacy; the mean FLARE-RA score in these patients was 5.4. Finally, 4 patients underwent drug tapering due to sustained remission; the mean FLARE-RA score in these patients was 1.1 (P 5 0.02 between groups).
DISCUSSION
This study showed that the self-administered FLARE-RA questionnaire (11 items) is a valid instrument. It can be used to detect the occurrence of RA flare at the time of the visit to the physician or, more importantly, during the months preceding the visit. The major strength of the FLARE-RA instrument is that it includes in a single tool the disease flare characteristics that have been identified by RA patients or rheumatologists using a parallel development process (1 for patients and 1 for physicians) based on rigorous methodology (10) . This process was necessary because several studies have shown that the concept of flare in RA is not univocal, with substantial divergence in the perception of physicians and patients (7) (8) (9) 11, 33) .
The data in the current study demonstrate the dimensional nature of the questionnaire, which is consistent with our previous work and that of the OMERACT group (9, 10) . Both physicians and patients who participated in these studies acknowledged that RA flare was only 1 unique concept corresponding to a transient change in disease activity that may result in loss of treatment efficacy and worse outcomes (7, 8, 10, 12, 15, 34) . The disentanglement of RA flares into joint-related symptoms (e.g., joint pain, swelling, or stiffness) and more general subjective features (e.g., fatigue, irritability, or aggressiveness toward relatives) was also noted (9, 10, 33) . Interestingly, our principal components analysis confirmed this finding by identifying 2 subdomains, 1 driven by arthritis-related symptoms and the other driven by more general feelings or characteristics.
Another important strength of the current study relates to the rigorous methodology used to establish the content validity of the FLARE-RA. Besides the involvement of patients, physicians, and health professionals in developing the instrument (10), modern measurement models were used to calibrate the instrument, which allowed for reducing the questionnaire to the final selection of 11 informative items. Scaling showed an acceptable interval scale metric, with no differential item functioning, and high convergent validity with other indices of disease activity measured at the same time as the flare survey. In addition, the study provided provisional evidence of a moderate-to-strong correlation between FLARE-RA and overall disease activity in the prior 3 months using another surrogate of disease activity, especially in patients with low disease activity or in remission at the time of the visit. Actually, the instrument performed better in this population than in patients with moderate-to-high disease activity, which could be interpreted as a strength, because it brings relevant information specifically when physician assessment is satisfactory in terms of achievement of the therapeutic objective.
Therefore, the aim of the FLARE-RA questionnaire is not to be a new self-assessment of disease activity (several others are already available [16] [17] [18] ) but rather an aid to identify patients with fluctuating disease activity and suboptimal control of their disease. There are several reasons for this. Rheumatologist appointments may be spaced out, and the time needed to secure an appointment in case of a flare may be long, depending on the density of rheumatologists in the country or region. Thus, RA flares might be considerably underestimated when the patient is not experiencing the flare at the consultation and/or he or she forgets to mention the occurrence of 1 or several flares that occurred since the last appointment.
In previous studies, a nurse-led helpline for patients has been proposed, in case of problems related to the disease or its treatment (35) (36) (37) . Such an organization with a rheumatology clinical nurse could substantially improve the quality of RA care by reducing the number of routine appointments and optimizing both physician and patient time. However, all rheumatology offices or departments do not have such a skilled staff. The FLARE-RA questionnaire could be an alternative means by which to collect adequate information (i.e., a disease flare) and enable scheduling of an anticipated appointment. In addition, flares are likely to be more frequent, with tapering strategies increasingly being implemented in daily practice and a significantly increased risk of flare and relapse (13, (38) (39) (40) (41) .
Our study also has some limitations. The scoring method has not been completely established. The FLARE-RA score was based on an arithmetic mean of the 11 items without any weighting, because differential ranking has not been established to give more weight to 1 or several items. Currently, the score reflects a quantity of flare or disease activity over a given period between 2 consultations with the physician. The predictive value of the score, in terms of future joint damage and disability, needs to be assessed in a longer-term prospective study. In addition, a threshold remains to be identified that separates 2 patient profiles: one of the profiles was characterized by residual "normal" or "unavoidable" symptoms, translating to the presence of RA per se, because patients often mentioned residual symptoms such as "I feel my joints" or "I had a bad day today" (33) , and the other characterized by true fluctuations of disease activity predicting further progression of joint damage and disability, as previously reported (15) . The foreseen longitudinal study will also enable this.
In conclusion, the FLARE-RA self-administered questionnaire, an 11-item scale with 2 subscales (arthritis subscale and general symptom subscale) developed jointly by patients and health care professionals, demonstrated good psychometric properties, validity, and scale invariance across age, sex, and flare occurrence. It enables the detection of flare occurrence between visits to the physician for patients with RA.
Additional validation studies remain to be conducted to identify the relevant threshold for FLARE-RA scores to detect a flare as well as to demonstrate the prognostic value of these scores in terms of RA overall control.
